Our @LDH™ formulation technology’s ability to intercalate acidic cannabinoids is a game-changer. This ensures consistent and stable formulations and enhances the shelf life, potency, and bioavailability of acidic cannabinoids.
Stability is paramount in the world of acidic cannabinoids. Mingowood Pharmacal spearheads innovation with its revolutionary @LDH™ formulation technology, providing a transformative solution for stabilizing these vital compounds.
Acidic cannabinoids, particularly CBDA, THCA, CBGA, and CBCA, are subject to rapid degradation from the time of purification. Environmental factors like light, heat, and oxygen degrade acidic cannabinoids, decreasing their potency, efficacy, and shelf life, thereby diminishing their therapeutic benefits.
Mingowood Pharmacal's @LDH™ formulation technology acts as a shield, intercalating acidic cannabinoids in layered hydroxides to safeguard their active compounds. This innovative approach creates a stable matrix, shielding against external elements and ensuring extract integrity from production to consumption.
Mingowood Pharmacal's @LDH™ formulation technology empowers products with unmatched stability. Whether you are developing wellness products, pain relief formulations, or ethical pharmaceuticals, partner with Mingowood to unlock the full potential of stability with @LDH™.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.